Stoke Therapeutics Inc’s recent filing unveils that its 10% Owner Skorpios Trust unloaded Company’s shares for reported $30.6 million on Jun 04 ’25. In the deal valued at $10.20 per share,3,000,000 shares were sold. As a result of this transaction, Skorpios Trust now holds 3,906,181 shares worth roughly $45.55 million.
Then, Ticho Barry sold 6,471 shares, generating $64,892 in total proceeds. Upon selling the shares at $10.03, the CHIEF MEDICAL OFFICER now owns 25,782 shares.
Before that, Ticho Barry sold 1,745 shares. Stoke Therapeutics Inc shares valued at $17,450 were divested by the CHIEF MEDICAL OFFICER at a price of $10.00 per share. As a result of the transaction, Ticho Barry now holds 32,253 shares, worth roughly $0.38 million.
Chardan Capital Markets initiated its Stoke Therapeutics Inc [STOK] rating to a Buy in a research note published on December 20, 2024; the price target was $24. TD Cowen also remained covering STOK and has increased its forecast on March 26, 2024 with a “an Outperform” recommendation from previously “Market perform” rating.
Price Performance Review of STOK
On Tuesday, Stoke Therapeutics Inc [NASDAQ:STOK] saw its stock fall -0.34% to $11.66. Over the last five days, the stock has gained 2.64%. Stoke Therapeutics Inc shares have risen nearly 5.71% since the year began. Nevertheless, the stocks have fallen -33.45% over the past one year. While a 52-week high of $16.62 was reached on 02/05/25, a 52-week low of $5.35 was recorded on 04/09/25.
Levels Of Support And Resistance For STOK Stock
The 24-hour chart illustrates a support level at 11.46, which if violated will result in even more drops to 11.25. On the upside, there is a resistance level at 11.91. A further resistance level may holdings at 12.15.
